The historical rank and industry rank for Ganga Pharmaceuticals's ROE % or its related term are showing as below:
BOM:539680'
s ROE % Range Over the Past 10 Years
Min: 0.38 Med: 1.21 Max: 3.7
Current: 1.28
During the past 12 years, Ganga Pharmaceuticals's highest ROE % was 3.70%. The lowest was 0.38%. And the median was 1.21%.
BOM:539680's ROE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 6
vs BOM:539680: 1.28
Ganga Pharmaceuticals (BOM:539680) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ganga Pharmaceuticals ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's ROE % distribution charts can be found below:
* The bar in red indicates where Ganga Pharmaceuticals's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ganga Pharmaceuticals (BOM:539680) has a ROE % of 1.85% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ganga Pharmaceuticals and its competitors. This is 53% above median its historical median of 1.21. Over the past decade, Ganga Pharmaceuticals' ROE % has ranged from 0.38 to 3.70.
Is Ganga Pharmaceuticals' ROE % too high?
Ganga Pharmaceuticals' current ROE % of 1.85% is 53% above median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 3.70. The Drug Manufacturers industry median ROE % is 6.00. Ganga Pharmaceuticals' value of 1.85% is 69.2% below this industry median. Overall, Ganga Pharmaceuticals has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ganga Pharmaceuticals' ROE % compare to ZTS?
Ganga Pharmaceuticals' ROE % of 1.85% can be compared against companies in the Drug Manufacturers industry. The industry median ROE % is 6.00. Ganga Pharmaceuticals' value of 1.85% is 69.2% below this benchmark. Historically, Ganga Pharmaceuticals' own ROE % has ranged from 0.38 to 3.70 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 6.00, Ganga Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ganga Pharmaceuticals's current ROE % of 1.85% is 69.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ganga Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ganga Pharmaceuticals's current ROE % is 1.85%, which is 53% above median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ganga Pharmaceuticals stock overvalued right now?
Ganga Pharmaceuticals (BOM:539680) has a current ROE % of 1.85%. The stock's GF Value™ is ₹11.85, compared to a current price of ₹12.00 — trading 1.3% above its estimated fair value. The current ROE % is 1.85%, which is 53% above median its 10-year median of 1.21 and 69.2% below the Drug Manufacturers industry median of 6.00. Ganga Pharmaceuticals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ganga Pharmaceuticals (BOM:539680), the current ROE % is 1.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ganga Pharmaceuticals (BOM:539680) Overvalued in 2026?
Based on GuruFocus' analysis, Ganga Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹12.00 is trading 1.3% above its estimated GF Value™ of ₹11.85.
Key valuation signals for BOM:539680:
ROE %: 1.85% (53% above median its 10-year median of 1.21)
GF Value™: ₹11.85 vs. price of ₹12.00 (1.3% above fair value)
Industry Position: 69.2% below the Drug Manufacturers median
No single metric tells the full story. See the BOM:539680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ganga Pharmaceuticals Ltd is an India based producer of ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.
62GF Score
Get the complete analysis for BOM:539680
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539680 has been successfully added to your 
